News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Jul 2, 2012

  Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
• Jun 27, 2012

  Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease
• May 30, 2012

  Insmed Provides Corporate Update
• May 23, 2012

  Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
• May 16, 2012

  Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
• May 8, 2012

  Insmed Announces First Quarter 2012 Financial Results
• May 7, 2012

  Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
• Apr 24, 2012

  Insmed to Host 2012 First Quarter Earnings Conference Call
• Apr 16, 2012

  Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections
• Mar 13, 2012

  Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results
• Feb 28, 2012

  Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
• Feb 10, 2012

  Insmed Incorporated Provides Update on Clinical Program for ARIKACE®
• Jan 20, 2012

  Insmed Incorporated Provides Corporate Update
• Nov 14, 2011

  Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
• Nov 8, 2011

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011
• Oct 25, 2011

  Insmed to Host 2011 Third Quarter Earnings Conference Call
• Oct 24, 2011

  Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
• Oct 10, 2011

  Insmed Incorporated Provides Regulatory Update
• Sep 26, 2011

  Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
• Aug 11, 2011

  Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
• Aug 8, 2011

  Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
• Aug 1, 2011

  Insmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials
• Jul 26, 2011

  Insmed to Host 2011 Second Quarter Earnings Conference Call
• Jul 18, 2011

  Andrea Drucker Joins Insmed as General Counsel
• Jun 28, 2011

  Insmed Announces its Addition to the Russell 3000® Index
• Jun 10, 2011

  Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
• May 10, 2011

  Insmed Announces First Quarter 2011 Financial Results

  Insmed Announces First Quarter 2011 Financial Results
• Apr 26, 2011

  Insmed to Host 2011 First Quarter Earnings Conference Call

  Insmed to Host 2011 First Quarter Earnings Conference Call
• Mar 21, 2011

  Insmed Regains NASDAQ Compliance
• Mar 21, 2011

  Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
• Mar 10, 2011

  Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
• Mar 3, 2011

  Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
• Mar 2, 2011

  One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
• Mar 1, 2011

  Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
• Feb 24, 2011

  Insmed to Participate on Phase III and Beyond Panel at 2011 RBC Capital Markets Healthcare Conference
• Feb 23, 2011

  Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
• Dec 16, 2010

  NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
• Dec 2, 2010

  Insmed Incorporated and Transave, Inc. Announce Business Combination
• Nov 3, 2010

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
• Oct 26, 2010

  Insmed to Host Third Quarter 2010 Conference Call
• Aug 4, 2010

  Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2010
• Jul 28, 2010

  Insmed to Host Second Quarter 2010 Conference Call
• Jun 21, 2010

  Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
• May 6, 2010

  Insmed Announces First Quarter 2010 Financial Results
• Apr 22, 2010

  Insmed to Host First Quarter 2010 Conference Call
• Mar 22, 2010

  Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer
• Mar 15, 2010

  Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results
• Mar 4, 2010

  Insmed Regains NASDAQ Compliance
• Mar 3, 2010

  Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call
• Nov 6, 2009

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
• Oct 22, 2009

  Insmed To Host Third Quarter 2009 Conference Call
• Sep 16, 2009

  Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
• Aug 13, 2009

  Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
• Jul 31, 2009

  Insmed to Host Second Quarter 2009 Conference Call
• Jul 27, 2009

  Insmed Provides Update on Supply of IPLEX(TM)
• Jun 30, 2009

  Insmed Announces Addition to the Russell 3000(R) Index
• Jun 25, 2009

  Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
• Jun 15, 2009

  Insmed CEO Resigns Due to Health Concerns
• May 13, 2009

  Insmed Announces First Quarter 2009 Financial Results
• May 5, 2009

  Insmed Regains NASDAQ Compliance
• Apr 23, 2009

  Insmed to Host First Quarter 2009 Conference Call
• Apr 22, 2009

  Insmed to Host First Quarter 2009 Conference Call
• Mar 31, 2009

  Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
• Mar 30, 2009

  Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
• Mar 25, 2009

  Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
• Mar 11, 2009

  Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
• Mar 10, 2009

  Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
• Feb 26, 2009

  Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
• Feb 12, 2009

  Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
• Jan 21, 2009

  Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
• Dec 26, 2008

  Insmed to Appeal Delisting Notification From Nasdaq
• Dec 23, 2008

  Insmed Announces that NASDAQ Extends Temporary Suspension of Minimum Bid Closing Price Rule
• Nov 25, 2008

  Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
• Nov 18, 2008

  Insmed to Participate in Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation
• Nov 10, 2008

  Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
• Nov 5, 2008

  Insmed to Present at Upcoming Healthcare Conferences
• 
  Oct 30, 2008

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

  Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008

  • Photos 4
• Oct 22, 2008

  NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009
• Oct 21, 2008

  Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
• Oct 20, 2008

  Insmed to Host Third Quarter 2008 Conference Call
• Oct 14, 2008

  Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
• Oct 14, 2008

  Insmed to Seek Shareholder Approval for Reverse Split
• Sep 23, 2008

  Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
• Sep 15, 2008

  Insmed to Present at Biosimilars 2008 Conference
• Sep 4, 2008

  Insmed to Present at BioPharm Asia 2008 Conference
• Sep 3, 2008

  NASDAQ Hearing Panel Grants Insmed Request for Continued Listing on the NASDAQ Stock Market
• Aug 8, 2008

  Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
• Jul 28, 2008

  Jim Miller, Ph.D. Joins Insmed Therapeutic Proteins as Vice President of Process Development
• Jul 25, 2008

  Insmed to Host Second Quarter 2008 Conference Call
• Jul 25, 2008

  Insmed CEO to Present at Drug Discovery & Development Conference
• Jul 22, 2008

  Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
• Jul 21, 2008

  Insmed Provides Update on IPLEX(TM) Programs
• Jul 17, 2008

  Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
• Jul 14, 2008

  Insmed Retains RBC Capital Markets as Strategic Financial Advisor
• Jul 10, 2008

  Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
• Jul 9, 2008

  Insmed to Present at Collins Stewart Fourth Annual Growth Conference
• Jun 20, 2008

  Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
• May 8, 2008

  Insmed Announces First Quarter 2008 Financial Results
• May 8, 2008

  /C O R R E C T I O N -- Insmed Inc./
• Apr 29, 2008

  Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download